Management of Pulmonary Arterial Hypertension in Primary Care: Advancing Patient Outcomes through Improved Diagnosis and Individualized Treatment

Management of Pulmonary Arterial Hypertension in Primary Care: Advancing Patient Outcomes through Improved Diagnosis and Individualized Treatment

On-Demand Webcast
Faculty

Kelly Chin, MD
Associate Professor of Internal Medicine
Pulmonary and Critical Care Division
Director, Pulmonary Hypertension Program
UT Southwestern Medical Center
Dallas, Texas

Intended Learners

This activity is designed for primary care physicians, family medicine specialists, internists, pediatricians, nurse practitioners, nurses, physician assistants, pharmacists, registered dietitians, certified diabetes educators, and other related healthcare professionals involved in the treatment of patients at risk for cardiometabolic syndrome. 

Learning Objectives

After completing this activity, participants should be able to:

  • Describe the risk factors, clinical characteristics, and diagnostic criteria/classification of PAH for timely and accurate differential diagnosis
  • Outline the etiologies and pathophysiology that underlie PAH and the resultant implications for therapeutic targeting
  • Differentiate among available PAH-specific treatments with respect to their mechanisms of action, efficacy, safety, and indications
  • Apply the latest clinical data, guideline recommendations, and therapeutic algorithms to facilitate the optimal identification, treatment, and referral of patients with PAH
Activity Overview

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10 question post-test with a score of 70% or better, and complete the evaluation form.

After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

ACPE Credit Policy

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. The reporting function into CPE Monitor will only be available for 60 days after your completion of the activity.  Under ACPE Policy, NACCME will not be able to report your credit to CPE Monitor after this 60 day period.

Release Date: October 16, 2018
Expiration Date: October 16, 2019
Estimated time to complete: 30 minutes

Participants who completed the live version of this activity are not eligible to receive credit for this enduring material.

For questions regarding this educational activity, please call 609-371-1137.

There is no fee associated with this activity.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs (please download here). A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation

    In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Save

CME

NACCME designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.

CPE

This enduring activity is approved for .5 contact hour (.05 CEUs) of continuing pharmacy education (JA0006201-0000-18-198-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.


Planning Committee

The planning committee is comprised of Michael Bloch, MD; Daniel Einhorn, MD; Timothy Harlan, MD; Peter H. Jones, MD; Jeffrey Levine, MD; Margo Minissian, PhD, ACNP; Leah Sarris, BS; Edward Shahady, MD and Donna Brophy, MaryEllen Fama, Emily Gibson, Jennifer Ilcyn, Mary Johnson, Todd Kunkler, Randy Robbin, Susan Yarbrough, NACCME.

Independent Clinical ReviewerPeter Oettgen, MD, Associate Professor of Medicine, Harvard Medical School, Director of Preventive Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Dr. Chin: Sildenafil for non-group 1 Pulmonary Hypertension treatment

Dr. Oettgen has disclosed no relevant financial relationships with any commercial interests.

Donna Brophy, MaryEllen Fama, Emily Gibson, Jennifer Ilcyn, Mary Johnson, Todd Kunkler, Randy Robbin, Susan Yarbrough disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed the following off-label/unapproved use(s) of drugs and/or devices will be discussed.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity is supported by an educational grant from Actelion Pharmaceuticles US, Inc.